The FDA on August 15, 2019 approved ROZLYTREK® for adults with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors are ROS1-positive. ROZLYTREK® is a product of Genentech Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on August 15, 2019 approved ROZLYTREK® for adults with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors are ROS1-positive. ROZLYTREK® is a product of Genentech Inc.
Advertisement